Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 10/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539858 | 0.80 | FDPS (0.36) | FDPSCYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL5984175 | 0.77 | GABRA1 (0.41) | IDO1L3MBTL1 | |
| SCHEMBL98042 | 0.75 | IDO1 (0.55) | IDO1ALDH1A1L3MBTL1 | |
| SCHEMBL28923 | 0.75 | IDO1 (0.55) | SMN1; SMN2IDO1ALDH1A1POLB | |
| SCHEMBL5519683 | 0.75 | IDO1 (0.55) | IDO1HSD17B10 | |
| SCHEMBL98917 | 0.75 | IDO1 (0.55) | SMN1; SMN2IDO1L3MBTL1 | |
| SCHEMBL133171 | 0.75 | MAOB (0.45) | ALDH1A1ADRA2BPTGS1 | |
| SCHEMBL1937871 | 0.75 | IDO1 (0.55) | IDO1 | |
| SCHEMBL541805 | 0.75 | ALOX15 (0.45) | FDPSCYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL15740590 | 0.73 | MEN1 (0.44) | CYP3A4ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 865 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133763-A2 | ALPP-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2024-06-27 | — | — | WO | claimed |
| US-20240082409-A1 | Modified peptide ligands for stable delivery of highly potent payloads to tumors: Method of making and using same | LAMHARZI NAJIB (US) | 2024-03-14 | — | — | US | claimed |
| WO-2024054821-A2 | TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| WO-2024028258-A1 | CONJUGATES OF PSMA-BINDING MOIETIES WITH CYTOTOXIC AGENTS | PHILOCHEM AG (CH) | 2024-02-08 | — | — | WO | claimed |
| US-20240000963-A1 | HYDROPHILIC LINKERS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2024-01-04 | — | — | US | claimed |
| EP-4294453-A1 | LINKER-PAYLOADS AND CONJUGATES THEREOF | Glykos Finland Oy (FI) | 2023-12-27 | — | — | EP | claimed |
| EP-4274583-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| EP-4262878-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-10-25 | — | — | EP | claimed |
| EP-4262987-A1 | ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | Almac Discovery Limited (GB) | 2023-10-25 | — | — | EP | claimed |
| CN-116806157-A | Linker-payload and conjugates thereof | 芬兰吉利科斯有限公司 | 2023-09-26 | — | — | CN | claimed |
| WO-2009012268-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| EP-1996625-A1 | ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2008-12-03 | — | — | EP | claimed |
| EP-1942944-A2 | MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS | Genentech, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| EP-1912677-A2 | PSMA ANTIBODY-DRUG CONJUGATES | Psma Development Company, L.L.C. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007140371-A2 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| WO-2007109567-A1 | ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2007100385-A2 | MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000963-A1 | HYDROPHILIC LINKERS AND CONJUGATES THEREOF | CD44, FOLR2, SLCO2B1 | FDPS 3679/4885CYP3A4 2715/4885ALOX15 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.